Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer have?
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer has 1,019 citations in the OpenAlex counts ScholarIQ stores.
When was Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer published?
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer has 2021 year in the ScholarIQ index.
What is the open-access status of Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer?
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer has bronze oa status in the ScholarIQ index.
What is the DOI of Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer?
The DOI for Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer is on the source record.
What is the PMID of Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer?
The PMID for Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer is on the source record.
What is the OpenAlex record for Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer?
The OpenAlex for Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer is on the source record.